Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 11, 2016 11:51 ET | Source: Genmab A/S

Ledende medarbejderes og deres nærtståendes transaktioner med aktier og tilknyttede værdipapirer i Genmab A/S

Selskabsmeddelelse København, Danmark, 11. november 2016 – I henhold til artikel 19 i forordning nr. 596/2014 om markedsmisbrug og gennemførelsesforordning 2016/523 har nedenstående personer givet...
November 11, 2016 11:51 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement Copenhagen, Denmark; November 11, 2016 – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, the persons below have...
November 10, 2016 12:43 ET | Source: Genmab A/S

Articles of Association for Genmab A/S

Genmab A/S has published its Articles of Association dated November 9, 2016. The Articles of Association can be found on Genmab’s website: http://ir.genmab.com/releases.cfm Contact: Rachel Curtis...
November 10, 2016 12:43 ET | Source: Genmab A/S

Selskabsvedtægter for Genmab A/S

Selskabsvedtægter for Genmab A/S dateret den 9. november 2016 er blevet offentliggjort. Selskabsvedtægterne er tilgængelige på Genmabs hjemmeside:...
November 10, 2016 10:23 ET | Source: Genmab A/S

CHMP afgiver positiv udtalelse og anbefaler Arzerra® (ofatumumab) i kombination med fludarabin og cyclofosfamid til behandling af recidiverende CLL

Pressemeddelelse CHMP afgiver positiv udtalelse for Arzerra til brug i kombination med fludarabin og cyclofosfamid til behandling af recidiverende CLL Den endelige afgørelse fra...
November 10, 2016 10:23 ET | Source: Genmab A/S

CHMP Issues Positive Opinion Recommending Arzerra® (ofatumumab) in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL

Media Release CHMP issued positive opinion for Arzerra for use in combination with fludarabine and cyclophosphamide in relapsed CLL Final decision from European Commission expected...
November 10, 2016 08:27 ET | Source: Genmab A/S

Genmab Announces Phase III Study of Daratumumab in Combination with Carfilzomib in Multiple Myeloma

Company Announcement New Phase III study combining daratumumab, carfilzomib and dexamethasone in relapsed/refractory multiple myeloma – dosing expected in 2017 First study under Clinical...
November 10, 2016 08:27 ET | Source: Genmab A/S

Genmab offentliggør fase III studie med daratumumab i kombination med carfilzomib til behandling af myelomatose

Selskabsmeddelelse Nyt fase III studie med kombination af daratumumab, carfilzomib og dexamethason til behandling af recidiverende/refraktær myelomatose – dosering forventes indledt i...
November 10, 2016 03:00 ET | Source: Genmab A/S

Genmabs kapitalmarkedsdag 2016

Pressemeddelelse Genmabs kapitalmarkedsdag 2016 afholdes i dag og webcastes også live Indlæg fra forskellige personer hos Genmab, herunder direktionen Blandt emnerne er en...
November 10, 2016 03:00 ET | Source: Genmab A/S

Genmab’s 2016 Capital Markets Day

Media Release Genmab’s 2016 Capital Markets Day taking place today, will also be webcast live Number of Genmab internal speakers, including Executive Management Topics include...